Jennifer R. Eads, MD
Medical Oncology

Jennifer R. Eads, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
View 1 additional location
Penn Medicine Provider

About me

  • Physician Lead, GI Clinical Research
  • Director, National Clinical Trials Network, Abramson Cancer Center
  • Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Tufts University School of MedicineMedical School
  • University Hospitals Cleveland Medical CenterResidency
  • University Hospitals Cleveland Medical CenterFellowship

Spoken languages

English
English

Reviews

Average Rating

643 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Great doctor.
Anonymous
October 2026
Is Dr eads was very patient and considerate with all my concerns and Fielding my questions. I had done considerable research on Dr eads and found her to be imminently qualified for my particular diagnosis and others. I would not hesitate to recommend Dr Eads.
Anonymous
October 2026
Excellent, knowledgeable, professional, kind physician.
Anonymous
October 2026
Dr Eads is very aware of the mindset and concerns of her patients.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Eads is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Morris N, Youngman J, Ordonez A, Mahmud N, Katona B, Eads JR Impact of radioligand therapy-induced hematologic toxicity on ability to receive cytotoxic chemotherapy in patients with gastroenteropancreatic neuroendocrine tumors , Digestive Disease Week (poster presentation): 2026


Lamarca A, Li D, Al Hallak MN, Anthony L, Baiyee Toegel E, Chandana SR, Dasari AN, Dayyani F, Demeure MJ, Eads JR, Garcia-Carbonero R, Halfdanarson TR, Henry JT, Hernandez T, Hernando J, Maluccio MA, Miao R, Pedregal M, Reilley MJ, Sahota S, Song MM, Spira AI, Thummalapalli R, DeBow D, Glatt DM, Zhou D, Metz DC, Zhang B, Bergsland E. First-in-human study of a novel, nonpeptide drug conjugate (CRN09682) in patients with somatostatin receptor 2-expressing tumors , European Neuroendocrine Tumor Society Annual Meeting (poster presentation): 2025


Capdevila J, Artamonova E, De Jesus Acosta A, Niccoli P, Toth M, Ramirez R, Hendifar A, Cingarlini S, Trikalinos NA, Quante M, Garcia-Carbonero R, Goder E, del Rivero J, Eads JR, Odeleye-Ajakaye A, Gozman A, Naik GS, Spada F Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase 2 LITESPARK-015 study. , European Society of Medical Oncology Annual Meeting: 2025


Capdevila J, Artamonova E, De Jesus Acosta A, Niccoli P, Toth M, Ramirez R, Hendifar A, Cingarlini S, Trikalinos NA, Quante M, Garcia-Carbonero R, Goder E, del Rivero J, Eads JR, Odeleye-Ajakaye A, Gozman A, Naik GS, Spada F Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase 2 LITESPARK-015 study , European Society of Medical Oncology Annual Meeting (oral presentation): 2025


Eads JR, Morelli MP, Olson D, Litten JB, Astrow SH, Pelster M A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers , J Clin Oncol: 2025


Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Fivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland J, Tabernero J, MATTERHORN Investigators Perioperative durvalumab in gastric and gastroesophageal junction cancer , N Engl J Med: 2025


Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O’Hara MH, Eads JR, King D, Shah MM, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA Incorporating circulating tumor DNA testing into clinical trials: a position paper by the National Cancer Institute GI Oncology circulating tumor DNA working group , JCO Precision Oncology: 2025


Eads JR Episode 26: Neuroendocrine Neoplasms: Focus on Immunotherapy , Los Angeles Carcinoid Neuroendocrine Tumor Foundation Podcast: 2024


Wornow S, DePietro D, Eads JR, Roses R, Soulen MC To treat or not to treat: resection of primary pancreatic neuroendocrine tumors in the metastatic setting , North American Neuroendocrine Tumor Society Annual Meeting: 2024


D’Souza JC, van Houten D, Reiss KA, Cohen RB, Kosteva JA, Schneider CJ, Eads JR, Teitelbaum UR, Soulen MC Initial outcomes of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 3 liver-dominant metastatic neuroendocrine tumors , North American Neuroendocrine Tumor Society Annual Meeting: 2024